Your browser doesn't support javascript.
loading
Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch.
Deceuninck, G; Lefebvre, B; Tsang, R; Betala-Belinga, J F; De Serres, G; De Wals, P.
Afiliação
  • Deceuninck G; Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Quebec City, Québec, Canada. Electronic address: genevieve.deceuninck.ciussscn@ssss.gouv.qc.ca.
  • Lefebvre B; Laboratoire de santé publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada.
  • Tsang R; Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
  • Betala-Belinga JF; Direction de santé publique de la Région sociosanitaire du Saguenay-Lac-Saint-Jean, Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Canada.
  • De Serres G; Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Quebec City, Québec, Canada; Direction des risques biologique et de la santé au travail, Institut national de santé publique du Québec, Quebec City, Québec, Canada; Department of Social and Preventive Medicine, Laval
  • De Wals P; Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Quebec City, Québec, Canada; Direction des risques biologique et de la santé au travail, Institut national de santé publique du Québec, Quebec City, Québec, Canada; Department of Social and Preventive Medicine, Laval
Vaccine ; 37(31): 4243-4245, 2019 07 18.
Article em En | MEDLINE | ID: mdl-31239214
ABSTRACT
In the Saguenay-Lac-Saint-Jean region of Quebec, 83% of the population ≤20 years (n ≅ 59,500) was immunized in 2014 with the four-component Serogroup B meningococcal vaccine to control a long-lasting outbreak caused by a virulent ST-269 Serogroup B Neisseria meningitidis clone. Following the campaign, invasive meningococcal B disease (B-IMD) incidence fell sharply in the target population from 11.4/100,000 in 2006-2014 to 0.4/100,000 in 2014-2018 (p < 0.0001). Five B-IMD cases occurred in the region from July 2014 to June 2018, including one vaccinated child, one unvaccinated young adult and 3 unvaccinated elderly adults. Estimate of direct vaccine protection was 79% [95%CI-231%;99%]. The overall campaign impact in the region taking into account the decrease in B-IMD incidence at provincial level was a 86% [95%CI-2%;98%] decrease in B-IMD risk. The campaign impact was mostly seen in the target age-group suggesting no herd effect among unvaccinated older adults.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinação / Programas de Imunização / Neisseria meningitidis Sorogrupo B / Meningite Meningocócica Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinação / Programas de Imunização / Neisseria meningitidis Sorogrupo B / Meningite Meningocócica Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article